With a landmark, 44-year-old agreement set to expire at the end of this month, the U.S. is facing one of its biggest China tests: Can...
Once upon a time, a U.S. company and a Chinese company developed an innovative and effective treatment for cancer. Will that ever happen again?
China had high hopes the pandemic would launch its domestic pharmaceutical industry. That didn't happen.
A look at the state of China’s healthcare system, including the cost of zero-Covid.
The precautions to reduce Covid-19 infections are simply not an option for many Chinese households.
The public’s rejection of the Chinese government's COVID rules raises the political stakes of the next controversial policy.
The Chinese government can still make policies that meet their citizens' expectations — but it will need to change course fast.
The Chinese strategy may be more economically sound than many assume, but it is time for the country to adopt a less severe approach.
BGI has entered the American genome sequencing market for the first time, forcing scientific innovation to clash with national security.
After securing contracts with the U.S. government, the Tianjin-based company's shares have surged 980 percent on the Shenzhen Stock Exchange.
With a mRNA vaccine finally in trials, will China change its Covid approach?
The journalist talks about his new Wuhan book, the "quite damaging" circumstantial evidence and demanding reciprocity with China.